| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
5'-O-DMT-Bz-rA does not have a specific biological target itself but serves as a chemical intermediate for the synthesis of cyclic dinucleotide compounds. Cyclic dinucleotides are important second messengers in both prokaryotic and eukaryotic cells, involved in various signaling pathways, including the STING pathway in innate immunity. As a protected nucleoside, the compound enables the controlled synthesis of these bioactive molecules.
|
|---|---|
| ln Vitro |
The in vitro activity of 5'-O-DMT-Bz-rA is assessed by its utility as a building block in the synthesis of cyclic dinucleotides. The efficiency of its incorporation into the cyclic dinucleotide structure and the purity of the final product are key measures of its utility. The compound itself is not biologically active but serves as a precursor for the synthesis of biologically active molecules.
|
| ln Vivo |
In vivo studies for 5'-O-DMT-Bz-rA are conducted on the cyclic dinucleotides synthesized using this building block rather than the intermediate itself. These cyclic dinucleotides are evaluated in animal models for their pharmacokinetic properties, biodistribution, and therapeutic efficacy in applications such as cancer immunotherapy (STING agonists). The protecting groups are removed during synthesis, and the final cyclic dinucleotide contains the natural adenosine nucleoside.
|
| Enzyme Assay |
For the synthesis of cyclic dinucleotides, 5'-O-DMT-Bz-rA is used as a starting material in a multi-step chemical synthesis. The compound is typically converted to the corresponding phosphoramidite and then used in standard phosphoramidite chemistry for the synthesis of the cyclic dinucleotide. The progress of the synthesis is monitored by HPLC, and the final product is characterized by mass spectrometry and NMR.
|
| Cell Assay |
For cellular studies, the cyclic dinucleotides synthesized using 5'-O-DMT-Bz-rA are tested in cell-based assays. Cells are treated with the cyclic dinucleotides, and their biological activity is assessed by measuring the activation of downstream signaling pathways, such as the STING pathway. The compounds' ability to induce interferon production or other immune responses is evaluated.
|
| Animal Protocol |
For in vivo evaluation of cyclic dinucleotides, mice or rats are administered the compounds via various routes. Pharmacokinetic parameters including half-life, clearance, and tissue distribution are determined. For therapeutic applications, efficacy is evaluated in appropriate disease models, such as tumor xenografts for cancer immunotherapy, with tumor volume or disease biomarkers monitored over time.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 5'-O-DMT-Bz-rA are characterized for the cyclic dinucleotides incorporating this building block rather than the intermediate itself. The compound has a molecular weight of 673.71 and a purity of 95%. It is typically handled as a solid and stored under recommended conditions to maintain stability. Detailed PK parameters depend on the specific cyclic dinucleotide synthesized.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 5'-O-DMT-Bz-rA is not explicitly detailed in the provided sources. As a chemical intermediate, standard laboratory safety precautions should be followed when handling it. It is intended for research use only and is not for human therapeutic applications. The compound's safety would be evaluated in the context of the final cyclic dinucleotide product rather than the intermediate itself.
|
| References | |
| Additional Infomation |
5'-O-DMT-Bz-rA is a nucleoside intermediate for the synthesis of cyclic dinucleotides. With a molecular formula of C38H35N5O7 and a molecular weight of 673.71, it features a benzoyl protecting group at the N6 position of adenine and a DMT protecting group at the 5' position. This research compound is for laboratory use only and has not been approved for clinical applications.
|
| Molecular Formula |
C38H35N5O7
|
|---|---|
| Molecular Weight |
673.71
|
| Exact Mass |
673.254
|
| CAS # |
81246-82-4
|
| PubChem CID |
14282135
|
| Appearance |
White to off-white solid powder
|
| Density |
1.36
|
| LogP |
4.796
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
50
|
| Complexity |
1050
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
COC1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=C(C=C3)OC)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)NC(=O)C7=CC=CC=C7)O)O
|
| InChi Key |
QPHBEJADZCSKCY-GONXPTGJSA-N
|
| InChi Code |
InChI=1S/C38H35N5O7/c1-47-28-17-13-26(14-18-28)38(25-11-7-4-8-12-25,27-15-19-29(48-2)20-16-27)49-21-30-32(44)33(45)37(50-30)43-23-41-31-34(39-22-40-35(31)43)42-36(46)24-9-5-3-6-10-24/h3-20,22-23,30,32-33,37,44-45H,21H2,1-2H3,(H,39,40,42,46)/t30-,32-,33-,37-/m1/s1
|
| Chemical Name |
N-[9-[(2R,3R,4S,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3,4-dihydroxyoxolan-2-yl]purin-6-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (148.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 13.16 mg/mL (19.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 131.6 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4843 mL | 7.4216 mL | 14.8432 mL | |
| 5 mM | 0.2969 mL | 1.4843 mL | 2.9686 mL | |
| 10 mM | 0.1484 mL | 0.7422 mL | 1.4843 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
